These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10570747)

  • 1. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model.
    Kaufman HL; Rao JB; Irvine KR; Bronte V; Rosenberg SA; Restifo NP
    J Immunother; 1999 Nov; 22(6):489-96. PubMed ID: 10570747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.
    Bronte V; Tsung K; Rao JB; Chen PW; Wang M; Rosenberg SA; Restifo NP
    J Immunol; 1995 May; 154(10):5282-92. PubMed ID: 7730632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen.
    Carroll MW; Overwijk WW; Surman DR; Tsung K; Moss B; Restifo NP
    J Natl Cancer Inst; 1998 Dec; 90(24):1881-7. PubMed ID: 9862625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
    Rao JB; Chamberlain RS; Bronte V; Carroll MW; Irvine KR; Moss B; Rosenberg SA; Restifo NP
    J Immunol; 1996 May; 156(9):3357-65. PubMed ID: 8617961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of a vaccinia colon oncolysate prepared with interleukin-2 gene-encoded vaccinia virus and interferon-alpha increases the survival of mice bearing syngeneic colon adenocarcinoma.
    Tanaka N; Sivanandham M; Wallack MK
    J Immunother Emphasis Tumor Immunol; 1994 Nov; 16(4):283-93. PubMed ID: 7881637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines.
    Chamberlain RS; Carroll MW; Bronte V; Hwu P; Warren S; Yang JC; Nishimura M; Moss B; Rosenberg SA; Restifo NP
    Cancer Res; 1996 Jun; 56(12):2832-6. PubMed ID: 8665522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity.
    Kaufman HL; Flanagan K; Lee CS; Perretta DJ; Horig H
    Vaccine; 2002 Mar; 20(13-14):1862-9. PubMed ID: 11906776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine.
    Bronte V; Carroll MW; Goletz TJ; Wang M; Overwijk WW; Marincola F; Rosenberg SA; Moss B; Restifo NP
    Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3183-8. PubMed ID: 9096367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model.
    Espenschied J; Lamont J; Longmate J; Pendas S; Wang Z; Diamond DJ; Ellenhorn JD
    J Immunol; 2003 Mar; 170(6):3401-7. PubMed ID: 12626601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice.
    Sivanandham M; Shaw P; Bernik SF; Paoletti E; Wallack MK
    Cancer Immunol Immunother; 1998 Jul; 46(5):261-7. PubMed ID: 9690454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
    McLaughlin JP; Schlom J; Kantor JA; Greiner JW
    Cancer Res; 1996 May; 56(10):2361-7. PubMed ID: 8625312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.
    Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
    Mol Ther; 2006 Jan; 13(1):183-93. PubMed ID: 16125469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.
    Wang M; Bronte V; Chen PW; Gritz L; Panicali D; Rosenberg SA; Restifo NP
    J Immunol; 1995 May; 154(9):4685-92. PubMed ID: 7722321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.
    Carroll MW; Overwijk WW; Chamberlain RS; Rosenberg SA; Moss B; Restifo NP
    Vaccine; 1997 Mar; 15(4):387-94. PubMed ID: 9141209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
    Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
    Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF.
    Qin H; Chatterjee SK
    Hum Gene Ther; 1996 Oct; 7(15):1853-60. PubMed ID: 8894677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine.
    Kantor J; Irvine K; Abrams S; Kaufman H; DiPietro J; Schlom J
    J Natl Cancer Inst; 1992 Jul; 84(14):1084-91. PubMed ID: 1619682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens.
    Overwijk WW; Surman DR; Tsung K; Restifo NP
    Methods; 1997 Jun; 12(2):117-23. PubMed ID: 9184376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.